Acute lymphoblastic leukaemia: Diagnosis and classification

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 4, 2002, Pages 597-621

  Kebriaei, Partow ^a   Anastasi, John ^a   Larson, Richard A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Acute lymphoblastic leukaemia; Cytogenetics; Diagnosis; DNA microarray; Fluorescence in situ hybridization (FISH); Prognosis

Indexed keywords

BCR ABL PROTEIN; HYBRID PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS TRANSLOCATION VARIANT 6; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; BLOOD CYTOLOGY; CANCER CLASSIFICATION; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 12; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 19; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; NUMERICAL CHROMOSOME ABERRATION; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; BONE MARROW BIOPSY; CEREBROSPINAL FLUID ANALYSIS; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CYTOGENETICS; CYTOMETRY; DIFFERENTIAL DIAGNOSIS; DIPLOIDY; DISEASE CLASSIFICATION; IMMUNOPHENOTYPING; INCIDENCE; LYMPHOBLASTOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MONOSOMY; PERTUSSIS; POLYMERASE CHAIN REACTION; TREATMENT PLANNING; TRISOMY;

EID: 0036954967     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2002.0224     Document Type: Review

References (107)

1. Hoelzer D & Gokbuget N. Recent approaches in acute lymphoblastic leukemia in adults. Critical Reviews in Oncology and Hematology 2000; 36: 49-58.
2. Farhi DC & Rosenthal NS. Acute lymphoblastic leukemia. Clinical and Laboratory Medicine 2000; 20: 17-28, vii.
3. Groves FD, Linet MS & Devesa SS. Patterns of occurrence of the leukaemias. European Journal of Cancer 1995; 31A: 941-949.
4. Greaves M. Childhood leukaemia. British Medical Journal 2002; 324: 283-287.
5. Pui CH. Childhood leukemias. New England Journal of Medicine 1995; 332: 1618-1630.
6. Takeuchi S, Koike M, Park S et al. The ATM gene and susceptibility to childhood T-cell acute lymphoblastic leukaemia. British Journal of Haematology 1998; 103: 536-538.
7. Greaves M. A natural history for pediatric acute leukemia. Blood 1993; 82: 1043-1051.
8. Skibola CF, Smith MT, Hubbard A et al. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood 2002; 99: 3786-3791.
9. Preston DL, Kusumi S, Tomonaga M et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiation Research 1994; 137(2 supplement): S68-S97.
10. Sandler DP, Shore DL, Anderson JR et al. Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow. Journal of the National Cancer Institute 1993; 85: 1994-2003.
11. Ben-David Y & Bernstein A. Friend virus-induced erythroleukemia and the multistage nature of cancer. Cell 1991; 66: 831-834.
12. Poiesz BJ, Ruscetti FW, Gazdar AF et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proceedings of the National Academy of Sciences of the USA 1980; 77: 7415-7419.
13. Andersen MK, Christiansen DH, Jensen BA et al. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992. British Journal of Haematology 2001; 114: 539-543.
14. Gur H, Koren V, Ehrenfeld M et al. Rheumatic manifestations preceding adult acute leukemia: characteristics and implication in course and prognosis. Acta Haematologica 1999; 101: 1-6.
15. Stoffel TJ, Nesbit ME & Levitt SH. Extramedullary involvement of the testes in childhood leukemia. Cancer 1975; 35: 1203-1211.
16. Ferrando AA & Look AT. Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukaemia. Seminars in Hematology 2000; 37: 381-395.
17. Mastrangelo R, Poplack D, Bleyer A et al. Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment. Medical and Pediatric Oncology 1986; 14: 191-194.
18. Price RA & Johnson WW. The central nervous system in childhood leukemia I. The arachnoid. Cancer 1973; 31: 520-533.
19. Tani E, Costa I, Svedmyr E & Skoog L. Diagnosis of lymphoma, leukemia, and metastatic tumor involvement of the cerebrospinal fluid by cytology and immunocytochemistry. Diagnostic Cytopathology 1995; 12: 14-22.
20. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. British Journal of Haematology 1976; 33: 451-458.
21. Bennett JM, Catovsky D, Daniel MT et al. The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. British Journal of Haematology 1981; 47: 553-561.
22. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001.
23. Lilleyman JS, Hann IM, Stevens RF et al. Blast cell vacuoles in childhood lymphoblastic leukaemia. British Journal of Haematology 1988; 70: 183-186.
24. Al-Rubei K, Rose PE & Hill FG. Morphological heterogeneity in childhood B cell acute lymphoblastic leukaemia. Journal of Clinical Pathology 1984; 37: 1348-1352.
25. Khalidi HS, Chang KL, Medeiros LJ et al. Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. American Journal of Clinical Pathology 1999; 111: 467-476.
26. Kim Y, Kang CS, Lee EJ et al. Acute lymphoblastic leukemia with maturation-a new entity with clinical significance. Leukemia 1998; 12: 875-881.
27. Darbyshire PJ & Lilleyman JS. Granular acute lymphoblastic leukaemia of childhood: a morphological phenomenon. Journal of Clinical Pathology 1987; 40: 251-253.
28. Schwarzinger I, Fodinger M, Scherrer R et al. Hypergranular acute lymphoblastic leukemia (ALL). Report of a case and review of the literature. Annals of Hematology 1993; 67: 301-303.
29. Schumacher HR, Desai SN, McClain KL et al. Acute lymphoblastic leukaemia-hand mirror variant. Analysis for endogenous retroviral antibodies in bone marrow plasma. American Journal of Clinical Pathology 1989; 91: 410-416.
30. Wegelius R. Preleukaemic states in children. Scandinavian Journal of Haemotology 1986; 45 (supplement): 133-139.
31. Wallis JP & Reid MM. Bone marrow fibrosis in childhood acute lymphoblastic leukaemia. Journal of Clinical Pathology 1989; 42: 1253-1254.
32. Macfarlane SD & Tauro GP. Acute lymphocytic leukaemia in children presenting with bone marrow necrosis. American Journal of Hematology 1986; 22: 341-346.
33. Ribeiro RC, Pui CH & Schell MJ. Vertebral compression fracture as a presenting feature of acute lymphoblastic leukemia in children. Cancer 1988; 61: 589-592.
34. Steinherz PG, Siegel SE, Bleyer WA et al. Lymphomatous presentation of childhood acute lymphoblastic leukemia. A subgroup at high risk of early treatment failure. Cancer 1991; 68: 751-758.
35. Longacre TA, Foucar K, Crago S et al. Hematogones: a multiparameter analysis of bone marrow precursor cells. Blood 1989; 73: 543-552.
36. Ott G, Kalla J, Ott MM et al. Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood 1997; 89: 1421-1429.
37. Huh YO & Ibrahim S. Immunophenotypes in adult acute lymphocytic leukemia. Role of flow cytometry in diagnosis and monitoring of disease. Hematology and Oncology Clinics of North America 2000; 14: 1251-1265.
38. Pileri SA, Ascani S, Milani M et al. Acute leukaemia immunophenotyping in bone-marrow routine sections. British Journal of Haematology 1999; 105: 394-401.
39. Braylan RC, Orfao A, Borowitz MJ & Davis BH. Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting. Cytometry 2001; 46: 23-27.
40. Bain BJ, Barnett D, Linch D et al. Revised guideline on immunophenotyping in acute leukaemias and chronic lymphoproliferative disorders. Clinical and Laboratory Haematology 2002; 24: 1-13.
41. Vasef MA, Brynes RK, Murata-Collins JL et al. Surface immunoglobulin light chain-positive acute lymphoblastic leukemia of FAB L1 or L2 type: a report of 6 cases in adults. American Journal of Clinical Pathology 1998; 110: 143-149.
42. Gassmann W, Loffler H, Thiel E et al. Morphological and cytochemical findings in 150 cases of T-lineage acute lymphoblastic leukaemia in adults. German Multicentre ALL Study Group (GMALL). British Journal of Haematology 1997; 97: 372-382.
43. Czuczman MS, Dodge RK, Stewart CC et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8364. Blood 1999; 93: 3931-3939.
44. Hann IM, Richards SM, Eden OB & Hill FG. Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia Trial XI (MRC UKALLXI). Medical Research Council Childhood Leukaemia Working Party. Leukemia 1998; 12: 1249-1255.
45. Larson RA, Dodge RK, Burns CP et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood 1995; 85: 2025-2037.
46. Matutes E, Morilla R, Farahat N et al. Definition of acute biphenotypic leukemia. Haematologica 1997; 82: 64-66.
47. Arber DA, Snyder DS, Fine M et al. Myeloperoxidase immunoreactivity in adult acute lymphoblastic leukemia. American Journal of Clinical Pathology 2001; 116: 25-33.
48. Rimsza LM, Larson RS, Winter SS et al. Benign hematogone-rich lymphoid proliferations can be distinguished from B-lineage acute lymphoblastic leukemia by integration of morphology, immunophenotype, adhesion molecule expression, and architectural features. American Journal of Clinical Pathology 2000; 114: 66-75.
49. van Wering ER, van der Linden-Schrever BE, Szczepanski T et al. Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease. British Journal of Haematology 2000; 110: 139-146.
50. + acute lymphoblastic leukemia. Leukemia 1996; 10: 795-802.
51. van Dongen JJ, Seriu T, Panzer-Grumayer ER et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731-1738.
52. Cave H, van der Werff ten Bosch J, Suciu S et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. New England Journal of Medicine 1998; 339: 591-598.
53. Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531-537.
54. Armstrong SA, Staunton JE, Silverman LB et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nature Genetics 2002; 30: 41-47.
55. Yeoh EJ, Ross ME, Shurtleff SA et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1: 133-143.
56. Heim S & Mittelman F. Cancer Cytogenetics, 2nd edn. New York: Wiley-Liss, 1995.
57. Faderl S, Kantarjian HM, Talpaz M & Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 1998; 91: 3995-4019.
58. Le Beau MM & Larson RA. Cytogenetics and Neoplasia. In Hoffman RB, Benz EJ & Shattil SJ et al (eds) Hematology: Basic Principles and Practice, 3rd edn. pp 848-869. Philadelphia: Churchill Livingstone, 2000.
59. Mittelman F. The Third International Workshop on Chromosomes in Leukemia. Lund, Sweden, July 21-25, 1980. Introduction. Cancer Genetics and Cytogenetics 1981; 4: 96-98.
60. Raimondi SC, Pui CH, Hancock ML et al. Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia. Leukemia 1996; 10: 213-224.
61. Trueworthy R, Shuster J, Look T et al. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. Journal of Clinical Oncology 1992; 10: 606-613.
62. Martinez-Climent JA. Molecular cytogenetics of childhood hematological malignancies. Leukemia 1997; 11: 1999-2021.
63. Belkov VM, Krynetski EY, Schuetz JD et al. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood 1999; 93: 1643-1650.
64. Ito C, Kumagai M, Manabe A et al. Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis. Blood 1999; 93: 315-320.
65. Raimondi SC, Roberson PK, Pui CH et al. Hyperdiploid (47-50) acute lymphoblastic leukemia in children. Blood 1992; 79: 3245-3252.
66. Pui CH, Raimondi SC, Dodge RK et al. Prognostic importance of structural chromosomal abnormalities in children with hyperdiploid (greater than 50 chromosomes) acute lymphoblastic leukemia. Blood 1989; 73: 1963-1967.
67. Secker-Walker LM, Prentice HG, Durrant J et al. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. British Journal of Haematology 1997; 96: 601-610.
68. Heerema NA, Nachman JB, Sather HN et al. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 1999; 94: 4036-4045.
69. Rubnitz JE, Downing JR, Pui CH et al. TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. Journal of Clinical Oncology 1997; 15: 1150-1157.
70. McLean TW, Ringold S, Neuberg D et al. TEL/AML-I dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 1996; 88: 4252-4258.
71. Rubnitz JE, Shuster JJ, Land VJ et al. Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study. Blood 1997; 89: 1143-1146.
72. Rubnitz JE, Behm FG, Pui CH et al. Genetic studies of childhood acute lymphoblastic leukemia with emphasis on p16, MLL, and ETV6 gene abnormalities: results of St Jude Total Therapy Study XII. Leukemia 1997; 111: 1201-1206.
73. Borkhardt A, Cazzaniga G, Viehmann S et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood 1997; 90: 571-577.
74. Maloney KW, McGavran L, Odom LF & Hunger SP. Acquisition of p16(INK4A) and p15(INK4B) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia. Blood 1999; 93: 2380-2385.
75. Loh ML, Silverman LB, Young ML et al. Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood 1998; 92: 4792-4797.
76. Jabber Al-Obaidi MS, Martineau M, Bennett CF et al. ETV6/AML1 fusion by FISH in adult acute lymphoblastic leukemia. Leukemia 2002; 16: 669-674.
77. Klein G. Immunoglobulin gene associated chromosomal translocations in B-cell derived tumors. Current Topics in Microbiology and Immunology 1999; 246: 161-167.
78. Fuhrmann G, Rosenberger G, Grusch M et al. The MYC dualism in growth and death. Mutation Research 1999; 437: 205-217.
79. Hoelzer D, Ludwig WD, Thiel E et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996; 87: 495-508.
80. Lee EJ, Petroni GR, Schiffer CA et al. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of Cancer and Leukemia Group B study 9251. Journal of Clinical Oncology 2001; 19: 4014-4022.
81. Schrappe M, Reiter A, Ludwig WD et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000; 95: 3310-3322.
82. Kamps MP. E2A-PBX1 induces growth, blocks differentiation, and interacts with other homeodomain proteins regulating normal differentiation. Current Topics in Microbiology and Immunology 1997; 220: 25-43.
83. Secker-Walker LM, Berger R, Fenaux P et al. Prognostic significance of the balanced t(1;19) and unbalanced der(19)t(1;19) translocations in acute lymphoblastic leukemia. Leukemia 1992; 6: 363-369.
84. Uckun FM, Sensel MG, Sather HN et al. Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. Journal of Clinical Oncology 1998; 16: 527-535.
85. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome. A Collaborative Study of the Group Francais de Cytogenetique Hematologique. Blood 1996; 87: 3135-3142.
86. Wetzler M, Dodge RK, Mrozek K et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood 1999; 93: 3983-3993.
87. Arico M, Valsecchi MG, Camitta B et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. New England Journal of Medicine 2000; 342: 998-1006.
88. Gleissner B, Gokbuget N, Bartram CR et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002; 99: 1536-1543.
89. Thiebaut A, Vernant JP, Degos L et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematology and Oncology Clinics of North America 2000; 14: 1353-1366.
90. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukaemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New England Journal of Medicine 2001; 344: 1038-1042.
91. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine 2001; 344: 1031-1037.
92. Rowley JD. The critical role of chromosome translocations in human leukemias. Annual Review of Genetics 1998; 32: 495-519.
93. Simone F, Polak PE, Kaberlein JJ et al. EAFI, a novel ELL-associated factor that is delocalized by expression of the MLL-ELL fusion protein. Blood 2001; 98: 201-209.
94. Dobson CL, Warren AJ, Pannell R et al. Tumorigenesis in mice with a fusion of the leukaemia oncogene MII and the bacterial IacZ gene. EMBO Journal 2000; 19: 843-851.
95. Ludwig WD, Rieder H, Bartram CR et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood 1998; 92: 1898-1909.
96. Raimondi SC, Frestedt JL, Pui CH et al. Acute lymphoblastic leukemias with deletion of 11q23 or a novel inversion (11)(p13q23) lack MLL gene rearrangements and have favorable clinical features. Blood 1995; 86: 1881-1886.
97. Johansson B, Moorman AV, Haas OA et al. Hematologic malignancies with t(4;11)(q21;q23) - a cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases. European 11q23 Workshop participants. Leukemia 1998; 12: 779-787.
98. Uckun FM, Sensel MG, Sun L et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 1998; 91: 735-746.
99. Carron C, Cormier F, Janin A et al. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 2000; 95: 3891-3899.
100. Heerema NA, Sather HN, Sensel MG et al. Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood 1999; 94: 1537-1544.
101. Yamada Y, Hatta Y, Murata K et al. Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. Journal of Clinical Oncology 1997; 15: 1778-1785.
102. Kees UR, Burton PR, Lu C & Baker DL. Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome. Blood 1997; 89: 4161-4166.
103. Stegmaier K, Pendse S, Barker GF et al. Frequent loss of heterozygosity at the TEL gene locus in acute lymphoblastic leukemia of childhood. Blood 1995; 86: 38-44.
104. Kanerva J, Niini T, Vettenranta K et al. Loss at 12p detected by comparative genomic hybridization (CGH): association with TEL-AML1 fusion and favorable prognostic features in childhood acute lymphoblastic leukemia (ALL). A multi-institutional study. Medical and Pediatric Oncology 2001; 37: 419-425.
105. Hayashi Y, Raimondi SC, Look AT et al. Abnormalities of the long arm of chromosome 6 in childhood acute lymphoblastic leukemia. Blood 1990; 76: 1626-1630.
106. Merup M, Moreno TC, Heyman M et al. 6q deletions in acute lymphoblastic leukemia and non-Hodgkin's lymphomas. Blood 1998; 91: 3397-3400.
107. Heerema NA, Sather HN, Sensel MG et al. Clinical significance of deletions of chromosome arm 6q in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Leukemia and Lymphoma 2000; 36: 467-478.